Glucagen Hypokit

Glucagen Hypokit is a prescription‑only glucagon injection marketed in the European Union. The product contains the peptide hormone glucagon as its active ingredient; the specific strength and dosage form are not publicly disclosed, but it is supplied for intramuscular, intravenous, or subcutaneous administration. Glucagen Hypokit belongs to the antihypoglycemic therapeutic class and is used by healthcare professionals to rapidly increase blood glucose in emergency situations.

Glucagen Hypokit is indicated for the rapid treatment of severe hypoglycemia and for specific overdose scenarios where glucose elevation is required. It is administered by qualified medical personnel when oral glucose intake is ineffective or contraindicated. - Emergency reversal of insulin‑induced severe hypoglycemia in adults and children. - Management of hypoglycemia unawareness when prompt glucose restoration is critical. - Treatment of hypoglycemia associated with prolonged fasting or malnutrition. - Counteracting hypoglycemia resulting from beta‑blocker or calcium channel blocker overdose. - Use in peri‑operative settings where rapid glucose elevation may be needed.

Glucagen Hypokit may cause transient physiological responses following injection, reflecting its intended effect on blood glucose and the body's reaction to the peptide.

Common: - Nausea, vomiting, or abdominal discomfort. - Flushing or warmth at the injection site. - Transient headache or dizziness. - Mild sweating or feeling of heat. - Temporary increase in heart rate.

Serious: - Severe allergic reaction, including rash, itching, or swelling. - Rapid heart rhythm disturbances (arrhythmia). - Marked hypertension or hypotension requiring medical attention. - Persistent hypoglycemia despite treatment, indicating possible dosing error. - These effects are generally short‑lived, but any unexpected or severe reaction should be reported to a healthcare professional promptly. - Monitoring of vital signs is recommended after administration to ensure patient safety.

Glucagen Hypokit should be used with attention to patient history and clinical setting, as certain conditions may increase the risk of adverse outcomes. - Known hypersensitivity to glucagon or any excipients. - History of pheochromocytoma or adrenal medullary disease. - Cardiovascular disease, especially recent myocardial infarction. - Pregnancy or breastfeeding status, due to limited safety data. - Use in pediatric patients requires weight‑based dosing considerations. - Concomitant use of beta‑blockers may mask typical symptoms. - Severe renal or hepatic impairment may affect glucagon metabolism. - Patients with pheochromocytoma should be monitored for hypertensive crises.

Glucagen Hypokit can interact with other medications, potentially altering its efficacy or increasing the risk of adverse events.

Avoid: - Concurrent use with other glucagon products or high‑dose glucagon analogues. - Administration together with potent vasoconstrictors that may exacerbate hypertension. - Co‑administration with epinephrine may lead to unpredictable glucose fluctuations.

Use with caution: - Beta‑blockers, which may blunt the typical tachycardia response. - Calcium channel blockers, as they can affect cardiovascular response. - Insulin therapy, requiring careful timing to avoid recurrent hypoglycemia. - Patients on MAO inhibitors should be observed for exaggerated cardiovascular effects. - Concurrent use of diuretics may affect fluid balance and blood pressure after glucagon administration.